LISATA THERAPEUTICS, INC.
Public company- Headquarters
- BASKING RIDGE, New Jersey
- Ticker
- LSTA
- CIK
- 0000320017
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| Class III member of the BoardJeffrey Farrow | Oct 14, 2026 | Appointed |
| directorTed W. Love, M.D. | Sep 17, 2026 | Appointed |
| CMOKristen K. Buck, M.D. | Aug 4, 2026 | Departed |
Related companies
Same industry and state, with recent events.
- BRISTOL MYERS SQUIBB CO
WARN notice: Princeton, NJ
- JOHNSON & JOHNSON
WARN notice: New Brunswick, NJ
- Merck & Co., Inc.
WARN notice: Rahway, NJ
- ELITE PHARMACEUTICALS INC /NV/
Class I director appointed: John W. LaRocca, Esq.
- Executive appointment
Class III member of the Board appointed: Jeffrey Farrow
Jeffrey Farrow was named Class III member of the Board of LISATA THERAPEUTICS, INC., effective October 13, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Oct 14, 2026Role: Class III member of the Board
- Executive appointment
director appointed: Ted W. Love, M.D.
Ted W. Love, M.D. was named director of LISATA THERAPEUTICS, INC., effective September 17, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 17, 2026Role: director
- Executive departure
CMO departs: Kristen K. Buck, M.D.
Kristen K. Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of LISATA THERAPEUTICS, INC., leaves the role, effective August 3, 2026. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Aug 4, 2026Role: Executive Vice President of R&D and Chief Medical Officer
Last verified Nov 8, 2026